Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Ziprasidone in Children and Adolescents with Psychotic Disorders
NCT00650611Phase 2Completed
- Sponsor
- Viatris
- Start
- Dec 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ziprasidone in schizophrenia, bipolar I disorder and schizoaffective disorder (2 arms), sponsored by Viatris. Primary endpoints: Adverse events at 27 weeks, Electrocardiograms and vital signs at 27 weeks and 1 more. Started Dec 2003; status: completed.
02
Drugs
ziprasidone
03
Conditions
schizophreniabipolar I disorderschizoaffective disorder
Beyond the preview
Go deeper on NCT00650611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00650611.